Bandingkan Harga & Kinerja UBC Medical Indonesia Tbk. (LABS) vs Reksa Dana Danareksa ETF Indonesia Top 40 (XDIF)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan UBC Medical Indonesia Tbk. dan Reksa Dana Danareksa ETF Indonesia Top 40: UBC Medical Indonesia Tbk. diperdagangkan di Rp148 (kapitalisasi pasar 576,7 M, volume 24 jam 3,48 jt), sedangkan Reksa Dana Danareksa ETF Indonesia Top 40 diperdagangkan di Rp407 (kapitalisasi pasar 29,47 M). Perbedaan utamanya: UBC Medical Indonesia Tbk. jauh lebih besar — sekitar 19,6× kapitalisasi pasar Reksa Dana Danareksa ETF Indonesia Top 40. Mana yang lebih baik tergantung tujuan investasimu.
| LABS | XDIF | |
|---|---|---|
Kapitalisasi Pasar | 576,7 M | 29,47 M |
Volume | 3,48 jt | — |
Lot | 34,82 rb | — |
Perputaran | 522,79 jt | — |
Harga Rata-rata | 150,13 | — |
Nilai Transaksi | 522,79 jt | — |
Harga Ekuilibrium Indikatif | 148 | — |
Volume Ekuilibrium Indikatif | 350 | — |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang UBC Medical Indonesia Tbk.
PT UBC Medical Indonesia (the Company) was established under the framework of Law of the Republic of Indonesia No. 20 year 1994 concerning the Foreign Capital Investment, as amended by Law No. 25 year 2007 concerning the Capital Investment based on Notarial Deed No. 01 dated 4 June 2014 of Novita Puspitarini, S.H., Notary in Jakarta. The Company started its commercial activities in October 2014. The parent entity as well as the ultimate parent entity of the Company is PT Optel Investama Mulia.
Selengkapnya di halaman LABS →
